Cover Image
Market Research Report

Global Ovarian Cancer Drugs Market 2019-2025

Published by Orion Market Research Pvt Ltd Product code 505712
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Global Ovarian Cancer Drugs Market 2019-2025
Published: January 3, 2020 Content info:
Description

Title:
Global Ovarian Cancer Drugs
Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors) and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) and Forecast 2019-2025.

The global ovarian cancer drugs market is expected to grow at a CAGR of 13.8% during the forecast period. Ovarian cancer is one of the riskiest cancers among all cancers in females. This cancer grows inside an ovary, resulting in abnormal growth of cells that have the tendency to attack or affect the functioning of other parts of the body, such as liver, lymph nodes, abdomen layers, the lining of the bowel and bladder. The ovarian cancer is rare; however, the risk in such kind of cancer is relatively high. According to the World Health Organization (WHO), around 10% of ovarian cancer cases are related to inherited genetic risk. The market is boosted by the increasing incidence of ovarian cancer, which is rising the need for more effective treatment. The high cost of ovarian cancer drugs and inaccurate diagnostic of ovarian cancer acts as a barrier for the growth of the market.

Geographically, the global ovarian cancer drugs market is classified into North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to have a significant share in the global market. The factors that are contributing to the market growth include the increasing prevalence of ovarian cancer, well-established healthcare infrastructure coupled with the presence of major market players in the region. Moreover, Asia-Pacific is estimated to exhibit considerable market growth in the global market during the forecast period. The rising awareness towards the ovarian cancer treatment in emerging economies, such as China and India, along with increasing healthcare expenditure and government initiatives are propelling the market growth in the region.

The global ovarian cancer drugs market is influenced by product development and advancements conducted by the market players. The key players operating in the global ovarian cancer drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Eli Lilly and Co., Bristol-Myers Squibb Co., and ImmunoGen Inc. These players are playing a significant role in the growth of the ovarian cancer drugs market by providing various products and adopting several strategies such as a merger and acquisition, partnerships and collaboration, technological development, and others. For instance, in December 2018, AstraZeneca PLC and Merck & Co., Inc. has received an FDA approval for olaparib (LYNPARZA) for the treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, who are under the complete or some response to first-line platinum-based chemotherapy.

Research Methodology

The market study of the global ovarian cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for a healthcare service provider, pharmaceutical companies, investing companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation

1. Global Ovarian Cancer Drugs Market Research and Analysis by Drug Class

2. Global Ovarian Cancer Drugs Market Research and Analysis by Therapy

The Report covers:

  • Comprehensive research methodology of the global ovarian cancer drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global ovarian cancer drugs market.
  • Insights about market determinants which are stimulating the global ovarian cancer drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Table of Contents
Product Code: OMR2020088

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Clovis Oncology, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. F. Hoffmann-La Roche Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. GlaxoSmithKline PLC
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Merck & Co., Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Ovarian Cancer Drugs Market by Drug Class
    • 5.1.1. PARP Inhibitors
    • 5.1.2. Angiogenesis Inhibitors
    • 5.1.3. PD-L1 Inhibitors
  • 5.2. Global Ovarian Cancer Drugs Market by Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Immunotherapy
    • 5.2.4. Others (Hormonal Therapy)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. AbbVie Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Boehringer Ingelheim GmbH
  • 7.5. Bristol-Myers Squibb Co.
  • 7.6. Clovis Oncology, Inc.
  • 7.7. DelMar Pharmaceuticals, Inc.
  • 7.8. Eli Lilly and Co.
  • 7.9. Exelixis, Inc.
  • 7.10. F. Hoffmann-La Roche Ltd.
  • 7.11. Genentech, Inc.
  • 7.12. GlaxoSmithKline PLC
  • 7.13. ImmunoGen Inc.
  • 7.14. Janssen Global Services, LLC, a division of Johnson & Johnson Services, Inc,
  • 7.15. Merck & Co., Inc.
  • 7.16. Mersana Therapeutics, Inc.
  • 7.17. Oasmia Pharmaceutical AB
  • 7.18. OncBioMune Pharmaceuticals Inc.
  • 7.19. Pfizer Inc.

LIST OF TABLES

  • 1. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 2. GLOBAL PARP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL ANGIOGENESIS INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL PD-L1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 6. GLOBAL OVARIAN CANCER DRUGS IN CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL OVARIAN CANCER DRUGS IN TARGETED THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL OVARIAN CANCER DRUGS IN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL OVARIAN CANCER DRUGS IN OTHER THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 14. EUROPEAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 16. EUROPEAN OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 18. ASIA-PACIFIC OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 19. ASIA-PACIFIC OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 20. REST OF THE WORLD OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 21. REST OF THE WORLD OVARIAN CANCER DRUG MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY DRUG CLASS, 2018 VS 2025 (%)
  • 2. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
  • 3. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD OVARIAN CANCER DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
Back to Top